B of A Securities Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has downgraded Bristol-Myers Squibb (BMY) from Buy to Neutral and reduced the price target from $68 to $60.
January 03, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb was downgraded by B of A Securities from Buy to Neutral, and the price target was lowered from $68 to $60.
Downgrades by analysts can lead to a negative perception among investors and potentially cause a short-term decline in the stock price. The reduction in the price target further suggests a lowered expectation of the company's future performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100